These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 24112272)

  • 21. Long-term efficacy of treatment of chronic hepatitis C with alpha interferon or alpha interferon and ribavirin.
    Barnes E; Webster G; Jacobs R; Dusheiko G
    J Hepatol; 1999; 31 Suppl 1():244-9. PubMed ID: 10622596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic hepatitis C--Swedish experts' meeting recommends combination treatment.
    Wejstål R; Fischler B; Glaumann H; Norkrans G; Reichard O; Sönnerbor A; Uhnoo I; Weiland O; ;
    Scand J Infect Dis; 2000; 32(5):465-70. PubMed ID: 11055647
    [No Abstract]   [Full Text] [Related]  

  • 23. Effects of combined antiviral therapy on asymptomatic mixed cryoglobulinemia in naive patients with chronic hepatitis C virus infection: a preliminary study.
    D'Amico E; Chincoli C; Cacciatore P; di Pasqua G; Cosentino L; Riario-Sforza G; Pennese E; Capani F; Palazzi C
    Dig Dis Sci; 2005 Dec; 50(12):2344-7. PubMed ID: 16416186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Viral kinetics can predict early response to alpha-interferon in chronic hepatitis C.
    Walsh KM; Good T; Cameron S; Thorburn D; McCruden EA; Mills PR; Morris AJ
    Liver; 1998 Jun; 18(3):191-5. PubMed ID: 9716230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of chronic hepatitis-C with standard interferon and ribavirin.
    Jadoon SA; Jadoon HA; Nazar HS
    J Ayub Med Coll Abbottabad; 2014; 26(2):212-5. PubMed ID: 25603680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapy for chronic hepatitis C.
    Pár A; Telegdy L; Dalmi L; Müller E;
    J Physiol Paris; 2001; 95(1-6):399-405. PubMed ID: 11595466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficiency of enterosorbent White Coal in the treatment of the patients with chronic viral hepatitis C and its influence on lipoperoxidation markers and endogenous intoxication in blood of patients].
    Frolov VM; Sotskaia IaA; Kruglova OV
    Lik Sprava; 2012; (5):119-25. PubMed ID: 23534280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Viral hepatitis C.
    Mascitelli L; Pezzetta F
    Lancet; 2004 Feb; 363(9409):661. PubMed ID: 14987902
    [No Abstract]   [Full Text] [Related]  

  • 29. The interferon signaling pathway genes as biomarkers of hepatitis C virus disease progression and response to treatment.
    Helbig KJ; Beard MR
    Biomark Med; 2012 Apr; 6(2):141-50. PubMed ID: 22448788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Erythrodermic Psoriasis and Hepatitis C Infection Treated with Pegylated Interferon and Anti-TNFα α(Etanercept) Therapy.
    Talat H; Wahid Z; Feroz F; Sajid M
    J Coll Physicians Surg Pak; 2017 Sep; 27(9):S77-S79. PubMed ID: 28969730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonsynonymous variant Pro70Ser (rs117648444) in IFNL4 gene identifies carriers of the rs368234815 ΔG allele with higher HCV RNA decline during the first 4 weeks of pegylated interferon and ribavirin therapy in HCV-1 patients.
    Galmozzi E; Aghemo A
    J Clin Virol; 2014 Apr; 59(4):274-5. PubMed ID: 24495847
    [No Abstract]   [Full Text] [Related]  

  • 32. Early decrease of interferon-gamma+ and interleukin-2+ T cells during combination treatment with interferon-alpha and ribavirin in patients with chronic hepatitis C.
    Krampera M; Fattovich G; Scupoli MT; Pizzolo G
    Am J Gastroenterol; 2000 Dec; 95(12):3670-3. PubMed ID: 11151933
    [No Abstract]   [Full Text] [Related]  

  • 33. A particular hepatitis C virus protease NS3 gene pattern in a patient not responding to interferon-ribavirin therapy.
    Vallet S; Nousbaum JB; Gouriou S; Legrand-Quillien MC; Goudeau A; Picard B
    Eur J Clin Microbiol Infect Dis; 2005 Jan; 24(1):79-80. PubMed ID: 15616841
    [No Abstract]   [Full Text] [Related]  

  • 34. Histamine and the response to IFN-alpha in chronic hepatitis C.
    Hellstrand K; Brune M; Mellqvist UH; Norkrans G; Lundberg PA; Hermodsson S; Wejstål R
    J Interferon Cytokine Res; 1998 Jan; 18(1):21-2. PubMed ID: 9475663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained virological response during exenatide treatment in a patient with hepatitis C and nonalcoholic steatohepatitis.
    Ellrichmann M; Vollmer K; Schrader H; Banasch M; Schmidt WE; Meier JJ
    Am J Gastroenterol; 2009 Dec; 104(12):3112-4. PubMed ID: 19956143
    [No Abstract]   [Full Text] [Related]  

  • 36. Response rates of standard interferon therapy in chronic HCV patients of Khyber Pakhtunkhwa (KPK).
    Ahmad B; Ali S; Ali I; Azam S; Bashir S
    Virol J; 2012 Jan; 9():18. PubMed ID: 22244529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hla-Cw7 allele as predictor of favorable therapeutic response to interferon-alpha in patients with chronic hepatitis C.
    Ivić I; Bradarić N; Puizina-Ivić N; Ledina D; Luksić B; Martinić R
    Croat Med J; 2007 Dec; 48(6):807-13. PubMed ID: 18074415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thyroid function outcomes after pegylated interferon-α and ribavirin therapy for chronic hepatitis C.
    Tran HA; Reeves GE; Ianna EA; Leembruggen N
    Endocr Pract; 2010; 16(6):934-9. PubMed ID: 20439240
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Microarrays and prediction of interferon response in chronic hepatitis C: not yet ready for prime time.
    Yeung E; Chung RT
    Clin Gastroenterol Hepatol; 2005 Dec; 3(12):1192-4. PubMed ID: 16361043
    [No Abstract]   [Full Text] [Related]  

  • 40. Anti-HCV IgM as predictor of response to interferon therapy in schistosomal patients with chronic hepatitis C.
    Derbala MF; Amer AM; El Defrawi IE
    Indian J Gastroenterol; 2006; 25(1):44. PubMed ID: 16567901
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.